Aggressive B-cell lymphomas: How many categories do we need?

Modern Pathology

Volumn 26, Issue , 2013, Pages 42-56

  Said, Jonathan W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aggressive B cell lymphoma; Burkitt; Double hit; High grade; Unclassifiable

Indexed keywords

RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CLINICAL FEATURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; EPSTEIN BARR VIRUS INFECTION; HEALTH SURVEY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOBLASTOID CELL; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; MOLECULAR PATHOLOGY; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CYTOGENETICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 84871920429     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.178     Document Type: Article

References (75)

1. Said J. Diffuse aggressive B-cell lymphomas. Adv Anat Pathol 2009;16:216-235.
2. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
3. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010;28:4191-4198.
4. Alencar AJ, Malumbres R, Kozloski GA, et al. Micro-RNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011;17:4125-4135.
5. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26: 1544-1552.
6. Gomez-Abad C, Pisonero H, Blanco-Aparicio C, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011;118:5517-5527.
7. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103-5110.
8. de Jong D, Balague Ponz O. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J Pathol 2011;223:274-282.
9. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/ leukaemia. Br J Haematol 2012;156:730-743.
10. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-4843.
11. Said J. Transformation to aggressive B-cell lymphoma: morphology, immunophenotype, and molecular characteristics. Appl Immunohistochem Mol Morphol 2003;11:199-205.
12. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011;29:1827-1834.
13. Dojcinov SD, Venkataraman G, Pittaluga S, et al. Agerelated EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011;117:4726-4735.
14. Wang J, Chen C, Lau S, et al. CD3-positive large B-cell lymphoma. Am J Surg Pathol 2009;33:505-512.
15. Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol 2010;34:882-891.
16. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-3467.
17. Slack GW, Tan K, Scott DW, et al. Co-expression of MYC and BCL2 protein in R-CHOP treated de novo diffuse large B-cell lymphoma predits poor outcome. Modern Pathol 2012;25(Supplement 2):370A.
18. Izquierdo F, Suarez D. CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1þ phenotype. Pathologic and molecular characterization of a single case. Hum Pathol 2012;43:1344-1345.
19. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology; e-pub ahead of print 29 May 2012.
20. Lucioni M, Novara F, Riboni R, et al. CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1þ phenotype. Pathologic and molecular characterization of a single case. Hum Pathol 2011;42:1204-1208.
21. Vela-Chavez T, Adam P, Kremer M, et al. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leuk Lymphoma 2011;52:458-466.
22. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-7078.
23. Chigrinova E, Mian M, Scandurra M, et al. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematol Oncol 2011;29:38-41.
24. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011;11:462-466.
25. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011;118:1350-1358.
26. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 2011;135:54-61.
27. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/ nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-4925.
28. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-1429.
29. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-207.
30. Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011;96:1888-1890.
31. Thunberg U, Enblad G, Berglund M. Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. Haematologica 2012;97:e3 author reply e4.
32. Bavi P, Uddin S, Bu R, et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol 2011;224:355-366.
33. Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012;26:1383-1390.
34. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-3365.
35. Cuccuini W, Briere J, Mounier N, et al. MYCþ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:4619-4624.
36. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25:145-156.
37. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
38. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
39. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracyclinebased chemotherapy with and without rituximab. J Clin Oncol 2008;26:447-454.
40. Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCHrituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-765.
41. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26:2103-2113.
42. Castillo JJ, Beltran BE, Song MK, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 2012;36:413-417.
43. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495.
44. Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011;118:510-522.
45. Sung CO, Kim SC, Karnan S, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011;117: 1291-1300.
46. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008;111:3200-3210.
47. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood 2009;113:7-10.
48. Kaune KM, Neumann C, Hallermann C, et al. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. Exp Dermatol 2011;20:331-335.
49. Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011;24:1046-1054.
50. Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factorkB activation. Mod Pathol 2012;25:968-982.
51. Adam P, Bonzheim I, Fend F, et al. Epstein-Barr viruspositive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011;18:349-355.
52. Qing X, Sun N, French SW, et al. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol 2011;135:977-978; author reply 8-9.
53. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95:1342-1349.
54. Boy SC, van Heerden MB, Babb C, et al. Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas. Oral Oncol 2011;47:883-887.
55. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol 2009;132:597-605.
56. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34: 1686-1694.
57. Hansra D, Montague N, Stefanovic A, et al. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol 2010;134:710-719.
58. Hsi ED, Lorsbach RB, Fend F, et al. Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011;136:183-194.
59. Chang ST, Liao YL, Lu CL, et al. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol 2007;128:339-344.
60. Linch DC. Burkitt lymphoma in adults. Br J Haematol 2012;156:693-703.
61. Smith SM. AIDS-related BL and CD4 count: a clue? Blood 2010;116:5435-5436.
62. Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011;25:1869-1876.
63. Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. WHO Press: Geneva, Switzerland, 2008.
64. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354: 2431-2442.
65. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354: 2419-2430.
66. Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med 2006;354: 2495-2498.
67. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-2331.
68. Wu D, Wood BL, Dorer R, et al. ‘Double-Hit’ mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol 2010;134:258-265.
69. Carbone A, Gloghini A, Aiello A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 2010;41:621-631.
70. Perry A, Dave B, Crockett D, et al. High-grade B-cell lymphoma with featues intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (grey zone lymphoma): A clinicopathologic analysis of 39 cases. Modern Pathol 2012;25(Supplement 2):361A.
71. Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 2012;118:1566-1573.
72. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273-2279.
73. Salaverria I, Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 2011;29:1835-1843.
74. Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 2011;29:1803-1811.
75. Janakiram M, Thirukonda VK, Sullivan M, Petrich AM. Emerging therapeutic targets in diffuse large B-cell lymphoma. Curr Treat Options Oncol; e-pub ahead of print 2 February 2012.